Silencing of DUSP6 Gene by RNAi-mediation Inhibits Proliferation and Growth in MDA-MB-231 Breast Cancer Cells: an in Vitro Study

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Sep 18

PMID 26379838

Citations 11

Authors

Hongming Song

Chenyang Wu

Chuankui Wei

Dengfeng Li

Kaiyao Hua

Jialu Song

Hui Xu

Lei Chen

Lin Fang

Affiliations

Soon will be listed here.

Abstract

Background: Dual-specificity phosphatase 6 (DUSP6) is a negative feedback mechanism of the mitogen-activated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK, p38), that is associated with cellular proliferation and differentiation. It has been reported that the expression of DUSP6 in different types of breast cancer is diverse and therefore it has altered functions in various types of breast cancer. Our aim was to explore the exact function of DUSP6 in triple-negative breast cancer cells (MDA-MB-231 cell) and to determine whether the suppression of DUSP6 by small interfering RNA (siRNA) and mircroRNA (miRNA) inhibits the growth of human MDA-MB-231 breast cancer cells.

Methods: DUSP6-siRNA was used to inhibit the expression of DUSP6 directly and miR-145 to inhibit the expression of DUSP6 either in MDA-MB-231 breast cancer cells and successful transfection being confirmed by Real-time PCR and Western Blotting. Down regulation of DUSP6 in MDA-MB-231 cells suppressed the cell proliferation as investigated by MTT assay and colony form assay. Transwell test and Scratch assay were conducted to investigate the migration and invasion of MDA-MB-231 cells. T-test (two-tailed) was used to compare differences between groups, and the significance level was set at P<0.05.

Results: DUSP6 mRNA expression and protein expression were reduced after transfection with DUSP6-siRNA directly and similar trend with transfection with miR-145. The treated group with DUSP6-siRNA or miR-145 suppressed MDA-MB-231 cells proliferation, migration and invasion, and meanwhile the cells were arrested at G0/G1 phase.

Conclusions: DUSP6 plays a role in triple-negative breast cancer cells that might promote growth in MDA-MB-231 triple-negative breast cancer cells.

Citing Articles

A distinct transcriptome characterizes neural crest-derived cells at the migratory wavefront during enteric nervous system development.

Stavely R, Hotta R, Guyer R, Picard N, Rahman A, Omer M Development. 2023; 150(5).

PMID: 36779913 PMC: 10108706. DOI: 10.1242/dev.201090.

Dual-specificity phosphatase (DUSP6) in human glioblastoma: epithelial-to-mesenchymal transition (EMT) involvement.

Zuchegna C, Di Zazzo E, Moncharmont B, Messina S BMC Res Notes. 2020; 13(1):374.

PMID: 32771050 PMC: 7414695. DOI: 10.1186/s13104-020-05214-y.

DUSP6 protects murine podocytes from high glucose‑induced inflammation and apoptosis.

Chen L, Wang Y, Luan H, Ma G, Zhang H, Chen G Mol Med Rep. 2020; 22(3):2273-2282.

PMID: 32705203 PMC: 7411363. DOI: 10.3892/mmr.2020.11317.

Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway.

Gao Y, Li H, Han Q, Li Y, Wang T, Huang C J Cancer. 2020; 11(11):3151-3164.

PMID: 32231719 PMC: 7097933. DOI: 10.7150/jca.37267.

Down-regulation of CCL17 in cancer-associated fibroblasts inhibits cell migration and invasion of breast cancer through ERK1/2 pathway.

Li J, Yang C, Yang J, Zou L Cancer Manag Res. 2019; 11:7439-7453.

PMID: 31496803 PMC: 6689663. DOI: 10.2147/CMAR.S211651.

References

Carthew R, Sontheimer E . Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55. PMC: 2675692. DOI: 10.1016/j.cell.2009.01.035. View

Chan D, Liu V, Tsao G, Yao K, Furukawa T, Chan K . Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis. 2008; 29(9):1742-50. DOI: 10.1093/carcin/bgn167. View

Manzano R, Martinez-Navarro E, Forteza J, Brugarolas A . Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers. Int J Oncol. 2014; 45(6):2250-66. PMC: 4215587. DOI: 10.3892/ijo.2014.2648. View

Li X, Luo Q, Wei C, Li D, Fang L . siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells. Int J Clin Exp Pathol. 2014; 7(1):92-100. PMC: 3885463. View

Bermudez O, Pages G, Gimond C . The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol. 2010; 299(2):C189-202. DOI: 10.1152/ajpcell.00347.2009. View

Furukawa T, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T . Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol. 2005; 18(8):1034-42. DOI: 10.1038/modpathol.3800383. View

Zhang J, Li X, Huang L . Non-viral nanocarriers for siRNA delivery in breast cancer. J Control Release. 2014; 190:440-50. PMC: 4142098. DOI: 10.1016/j.jconrel.2014.05.037. View

Okudela K, Yazawa T, Woo T, Sakaeda M, Ishii J, Mitsui H . Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol. 2009; 175(2):867-81. PMC: 2716981. DOI: 10.2353/ajpath.2009.080489. View

Uchino K, Ochiya T, Takeshita F . RNAi therapeutics and applications of microRNAs in cancer treatment. Jpn J Clin Oncol. 2013; 43(6):596-607. DOI: 10.1093/jjco/hyt052. View

10.

Li D, Chen L, Hu Z, Li H, Li J, Wei C . Alterations of microRNAs are associated with impaired growth of MCF-7 breast cancer cells induced by inhibition of casein kinase 2. Int J Clin Exp Pathol. 2014; 7(7):4008-15. PMC: 4129013. View

11.

Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S . miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 2014; 13:220. PMC: 4181414. DOI: 10.1186/1476-4598-13-220. View

12.

Ozpolat B, Sood A, Lopez-Berestein G . Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014; 66:110-6. PMC: 4527165. DOI: 10.1016/j.addr.2013.12.008. View

13.

Eades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q . lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res. 2014; 13(2):330-8. PMC: 4336811. DOI: 10.1158/1541-7786.MCR-14-0251. View

14.

Esposito C, Catuogno S, de Franciscis V . Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells. J RNAi Gene Silencing. 2014; 10:500-6. PMC: 4238741. View

15.

Piya S, Kim J, Bae J, Seol D, Moon A, Kim T . DUSP6 is a novel transcriptional target of p53 and regulates p53-mediated apoptosis by modulating expression levels of Bcl-2 family proteins. FEBS Lett. 2012; 586(23):4233-40. DOI: 10.1016/j.febslet.2012.10.031. View

16.

Diaz-Garcia C, Agudo-Lopez A, Perez C, Prieto-Garcia E, Iglesias L, Ponce S . Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer. Tumour Biol. 2014; 36(2):1199-206. DOI: 10.1007/s13277-014-2729-8. View

17.

Cheng Y, Ueno N . Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer. 2011; 19(3):191-9. PMC: 3860359. DOI: 10.1007/s12282-011-0276-3. View

18.

Zhang J, Wang L, Li B, Huo M, Mu M, Liu J . miR-145 downregulates the expression of cyclin-dependent kinase 6 in human cervical carcinoma cells. Exp Ther Med. 2014; 8(2):591-594. PMC: 4079406. DOI: 10.3892/etm.2014.1765. View

19.

Boufraqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y . miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014; 21(4):517-31. PMC: 8375571. DOI: 10.1530/ERC-14-0077. View

20.

Toniatti C, Jones P, Graham H, Pagliara B, Draetta G . Oncology drug discovery: planning a turnaround. Cancer Discov. 2014; 4(4):397-404. DOI: 10.1158/2159-8290.CD-13-0452. View